Neues von Alizyme!Alizyme Completes Preclinical Development of Obesity Drug ATL-962 - 500 Beiträge pro Seite

[pe1]

Alizyme Completes Preclinical Development of Obesity Drug ATL-962

Alizyme plc announces today that it has successfully completed the preclinical development programme of ATL-962, its lipase inhibitor for the
treatment of obesity. Subject to receiving approval from the Ethics Committee, recruitment of volunteers for the Phase I clinical trial will commence
in May.

The trial, which will be a first time in man study, will be carried out at a UK centre. It will assess the safety and tolerability of single doses of
ATL-962 in an ascending dose regimen and will involve up to 32 healthy volunteers.

Commenting on this announcement

Dr Richard Palmer, Chief Executive Officer of Alizyme said:

"We are delighted to have completed the preclinical development of ATL-962. This is a significant milestone for Alizyme as it is the
culmination of a discovery programme that started in September 1996 and resulted in the identification of ATL-962 as a development
candidate in April 1999. The progress of ATL-962 through preclinical development to Phase I clinical development on time and in less
than a year, is a testament to the skills and hard work of the team at Alizyme and of our collaborators on this programme."

[otto12]

hallo leute,
ein wenig aufwaertstrend taete der aktie ganz gut.
mal sehen, was draus wird ...
gruesse an alle aly`s von
otto, dem 12.

[Kaktus Koch]

Hi!
10:18, +38.89%
Ciao!